Palbonamo contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor used primarily in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Palbociclib works by slowing cancer cell division, helping to control tumor growth. It is usually given in combination with endocrine therapy such as letrozole or fulvestrant.

Mechanism of Action

• Palbociclib selectively inhibits CDK4 and CDK6, enzymes that regulate the cell cycle progression from G1 to S phase.

• By blocking these kinases, it halts cancer cell proliferation and induces cell cycle arrest.

• When combined with endocrine therapy, it enhances the anti-tumor effect in hormone-sensitive breast cancer.

  Uses

  • Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

    • Letrozole as initial endocrine-based therapy.

    • Fulvestrant in patients with disease progression following endocrine therapy.

  • Helps slow disease progression and prolong progression-free survival in advanced breast cancer.

    Adverse Effects

    • Low white blood cell count (neutropenia)

    • Fatigue or weakness

    • Nausea, diarrhea, or constipation

    • Hair thinning (alopecia)